Myriad Genetics (MYGN) Announces Accelerated $50M Share Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Myriad Announces $50 Million Accelerated Share Repurchase Program
November 19, 2018 7:05 AM ESTSALT LAKE CITY, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated share repurchase (ASR) agreement with Bank of America, N.A. under which the company will repurchase approximately $50 million of its common stock. Â Myriad currently has approximately $161 million remaining on its existing share repurchase authorization which has been approved by the companys board of directors.
We remain highly confident in the future growth prospects for the company and believe repurchasing shares at current levels will generate a... More
